16-Jul-2026
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Globe Newswire (Thu, 28-May 4:05 PM ET)
Globe Newswire (Tue, 26-May 4:05 PM ET)
Globe Newswire (Fri, 22-May 7:05 AM ET)
Globe Newswire (Fri, 22-May 7:00 AM ET)
Globe Newswire (Wed, 13-May 2:00 AM ET)
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Globe Newswire (Mon, 11-May 8:00 AM ET)
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Globe Newswire (Thu, 7-May 4:00 PM ET)
Market Chameleon (Fri, 20-Mar 5:59 AM ET)
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Assembly Biosciences trades on the NASDAQ stock market under the symbol ASMB.
As of July 16, 2026, ASMB stock price declined to $25.84 with 308,304 million shares trading.
ASMB has a beta of 0.65, meaning it tends to be less sensitive to market movements. ASMB has a correlation of 0.02 to the broad based SPY ETF.
ASMB has a market cap of $512.08 million. This is considered a Small Cap stock.
Last quarter Assembly Biosciences reported $8 million in Revenue and -$.54 earnings per share. This beat revenue expectation by $813,600 and exceeded earnings estimates by $.12.
In the last 3 years, ASMB traded as high as $39.71 and as low as $7.69.
The top ETF exchange traded funds that ASMB belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ASMB has outperformed the market in the last year with a return of +36.3%, while the SPY ETF gained +21.5%. However, in the most recent history, ASMB shares have underperformed the stock market with its stock returning -11.9% in the last 3 month period and -6.8% for the last 2 week period, while SPY has returned +7.3% and +0.8%, respectively.
ASMB support price is $25.56 and resistance is $27.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASMB shares will trade within this expected range on the day.